このレポートは完全なものではないが､臨床プロテオミクスの分野で期待感が高まっていることをはっきりと描けたのではないか｡MSを用いたプロテオミクス技術の臨床応用は人々が期待したほど速やかには進まなかったが､過去2,3年の間にこの分野の技術が大きく前進している｡
長年､期待されてきた本来強力な性質のこの技術がようやく臨床に採用され､そればかりでなく､特にがんに焦点が当てられているが､他にも循環器系疾患､代謝症候群､糖尿病､腎疾患､肝疾患その他複雑な障害に苦しむ患者にも広く応用される日が近いと考える専門家は多い｡
プロテオミクスを臨床に採用する勢いが今後促進されれば､長年待ち望んでいた個別患者治療の劇的な改善を伴う｢プレシジョン医療｣の実現に向けてさらにはずみがつくことが予想される｡
参考：
1.O’Neill, Michael D., “Obama Proposes $215 Million “Precision Medicine Initiative.” BioQuick Online News (January 30, 2015).
2.Bruderer R. et al. “Extending the Limits of Quantitative Proteome Profiling with Data-Independent Acquisition and Application to Acetaminophen Treated 3D Liver Microtissues.” Molecular Cell Proteomics 14(5): 140-1410 (May 2015).
3.Picotti P. et al., “High-Throughput Generation of Selected Reaction-Monitoring Assays for Proteins and Proteomes, Nature Methods 7(1): 43-46 (January 2010).
4.Gaik M. et al. “Structural Basis for Assembly and Function of the Nup82 Complex in the Nuclear Pore Scaffold.” Journal of Cell Biology 208(3): 283-297 (February 2, 2015).
5.Peterson A.C., Russell J.D., Bailey D.J., Westphall M.S., and Coon J.J., “Parallel Reaction Monitoring for High Resolution and High Mass Accuracy Quantitative, Targeted Proteomics.” Molecular & Cellular Proteomics 11(11):1475-88 (November 1, 2012).
6.Escher C, Reiter L, MacLean B, Ossola R, Herzog F, Chilton J, MacCoss M.J, Rinner O. Using iRT, a normalized retention time for more targeted measurement of peptides. Proteomics 12(8): 1111-1121. (April 2012).
7.Bonislawsky, Adam, “AB Sciex, ThermoFisher Tout New Mass Spec Launches at AACC.” Genome Web (August 1, 2014)
8.Vachani A. et al., “Validation of a Multiprotein Plasma Classifier to Identify Benign Lung Nodules.” J. Thoracic Oncology 10(4): 629-637 (April 2015).
9.Bonislawsky, Adam, “Applied Proteomics Prepping ELISA Version of CRC Test for Near-Term Release.” Genome Web (June 26, 2015).
10.“Biodesix Adds Biognosys’ Proteomics Technology to Its Diagnostic Development Capabilities; Collaboration Enables Protein Identification within Proteomic Signatures.” Biodesix Press Release (July 29, 2015).
11.Fony, Tony, “Nuclea Bio Plans Entry into Clinical Proteomics with Launch of Mass Spec-Based Assays in 2015.” Genome Web (February 17, 2015).
12.Bonislawsky, Adam, “Sera Planning 2015 Launch of PreTRM Proteomic Test to Assess Preterm Delivery Risk.” Genome Web (January 9, 2015).
13.“Bill & Melinda Gates Foundation Has Agreed to Join Series B Funding.” Sera Therapeutics Press Release (February 4, 2015).
14.Bonislawsky, Adam, “Applied Proteomics Prepping ELISA Version of CRC Test for Near-Term Release.” Genome Web (June 26, 2015).
15. “Agilent Technologies and Applied Proteomics Will Collaborate to Maximize Capabilities of Highly Multiplexed Protein Assays.” Applied Proteomics Press Release (March 7, 2013).
